You searched for bad - Page 5 of 7 - Journal for Clinical Studies

Current Edition

Europe

Is $9.7B too big a price for The Medicines Company? Novartis itself seems to think so…

When Novartis unveiled its $9.7 billion buyout of The Medicines Company a few days ago, several analysts suggested the price was too high. Turns out, the Swiss drugm...

12 December 2019 Europe | Regional News

Continue Reading →

Europe

Glenmark Gets FDA Warning Letter for Plant That Produced Defective Creams

India’s Glenmark has been having its manufacturing problems, what with recalls and complete response letters (CRLs). Now, to round things out, the FDA has issued a w...

8 October 2019 Europe | Regional News

Continue Reading →

Europe

Medicines Co. awaits its date with destiny

Investors in The Medicines Company have Sept. 2 circled in red on their calendars. That's the day the company plans to report the first pivotal results from late-...

22 August 2019 Europe | news | North America | Regional News

Continue Reading →

news

Regeneron gets cholesterol drug win where Praluent won’t go

(Credit: Flickr; Helge V. Keitel ) Regeneron Pharmaceuticals said its experimental drug evinacumab significantly lowered "bad" cholesterol levels 49% compared to...

22 August 2019 news | North America | Regional News

Continue Reading →

news

Laurus Labs launches Pregabalin Capsules in US market

Pregabalin Capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy Laurus Labs Limited, a Hyderabad based research...

25 July 2019 news | North America

Continue Reading →

news

ImmusanT cans phase 2 celiac trial after interim efficacy review

ImmusanT saw celiac disease as a good proving ground for its approach. (Pixabay) ImmusanT has stopped a phase 2 trial of its lead candidate in celiac disease aft...

27 June 2019 news | North America | Regional News

Continue Reading →

Europe

Varian completes acquisition of Cancer Treatment Services International

This transaction will accelerate identification of unmet clinical and operational needs to facilitate advances in technology and services Varian has announced that...

20 June 2019 Europe | news | North America

Continue Reading →

Europe

Allergan puts Vraylar on blockbuster track with new bipolar depression nod

Credit Suisse analysts predict Allergan's Vraylar could hit $1.16 billion in sales by 2026. (Allergan) Allergan, badly in need of good news, finally has some to ...

30 May 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

Long-term heart data reassures for Medicines Co.

The Medicines Company on Saturday released data from a long-term safety study of its experimental cholesterol-lowering drug inclisiran in heart disease patients, ...

23 May 2019 Europe | news | North America | Regional News

Continue Reading →

Europe

‘Super’-responder analysis gives more power to Viking’s fatty liver drug

Researchers Monday presented more complete results from Viking Therapeutics' 12-week Phase 2 study of VK2809 at The Liver Meeting 2018, after previously announcing in...

15 November 2018 Europe | news | North America

Continue Reading →